TrialThe New England journal of medicine2021
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Haydar Frangoul et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,029 papers cite itlatest 60 shown
this paperpooled ittrialcites it